Baird Rates REGENXBIO (RGNX) buy, $32 Price Target
Baird's analyst maintains a bullish stance on REGENXBIO Inc., setting a price target of $32, a 220.96% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Baird rated REGENXBIO Inc. ($RGNX) "buy" with a $32 price target on June 22, 2026.
Since the rating, $RGNX is up 30.4% after 1 week, up 12.5% after 1 month and down 23.7% to date (from the $9.07 close on Jun 22, 2026).
RGNX
REGENXBIO Inc.
Key Points
- On June 22, 2026, Baird reiterated its buy rating on REGENXBIO Inc. with a price target of $32.
- Baird's $32 price target implies 220.96% upside from REGENXBIO Inc.'s ($RGNX) current $9.97 share price.
- Shares of NasdaqGS:RGNX traded at $7.80 on Tuesday, with a 52-week range of $5.46 to $16.19.
- Insiders made significant purchases in late May, and several analysts maintain a buy rating.
Get $RGNX trade alerts by text
We text you when insiders, Congress or big funds trade $RGNX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated REGENXBIO Inc. alert may contain errors. Disclosures
On June 22, 2026, Baird reiterated its buy rating on REGENXBIO Inc. (NasdaqGS:RGNX), setting a price target of $32. The analyst, Brian Skorney, continues to express confidence in the biotechnology company's prospects.
Baird vs. the S&P 500
Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in REGENXBIO Inc.
In recent institutional activity, BlackRock, Inc. grew its holdings by 25,997 shares, ending with 5,782,808 shares worth about $48.5 million. State Street Corp increased its position by 444,749 shares, bringing its total to 2,731,485 shares valued at approximately $22.9 million. Meanwhile, JPMorgan Chase & Co reduced its stake by 69,702 shares, now holding 3,483,800 shares worth $27.1 million. Morgan Stanley added 51,369 shares, resulting in a total of 2,066,157 shares valued at $17.3 million. Vanguard Capital Management LLC opened a new position with 2,007,146 shares, valued at around $16.8 million.
REGENXBIO Inc. Stock Up 24.2%
Shares of NasdaqGS:RGNX traded near $7.80 on Tuesday. REGENXBIO Inc. has a market cap of approximately $468.9 million and a forward P/E ratio that is not meaningful as the company is not currently profitable. The stock's 52-week low is $5.46, and its high is $16.19. The 50-day moving average is $7.95, while the 200-day moving average is $10.34. The company maintains a current ratio of 2.62 and a quick ratio of 2.45, with a high debt-to-equity ratio of 1178.24.
$RGNX price target
REGENXBIO Inc. daily closes and this analyst's $32 target. Not advice.
Recent Earnings
REGENXBIO Inc. reported revenue of $87.8 million, although it experienced a decline of 92.8% in revenue growth. The company recorded a negative return on equity of -196.43% and a net margin of 0.0%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at REGENXBIO Inc.
Several insiders made significant stock purchases on May 29, 2026. Daniel Tasse, Kenneth Mills, David Stump, Allan Fox, and Alexandra Glucksmann each acquired 46,600 shares, while Kenneth Mills and Allan Fox also purchased an additional 9,807 shares. These transactions were not planned under Rule 10b5-1.
Analysts Set New Price Targets
On June 22, 2026, Baird maintained its buy rating for REGENXBIO Inc. with a $32 price target. Leerink Partners also maintained a buy rating, setting a target of $18. Earlier in June, HC Wainwright & Co. reiterated a buy rating with a $26 target. The consensus among analysts is a "buy" rating with an average target price of $23.82, based on opinions from 11 analysts.
About REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company based in Rockville, Maryland. It focuses on developing gene therapies for treating genetic disorders. The company's NAV Technology Platform is a proprietary system used to deliver functional genes to cells. REGENXBIO is working on several gene therapy candidates, including treatments for retinal diseases and muscular dystrophy. The company collaborates with other biotech firms and has partnerships with AbbVie Global Enterprises and Nippon Shinyaku.
Bottom Line
Baird's reiterated buy rating and $32 price target for REGENXBIO Inc. highlight continued confidence in its potential. The stock's current trading price and recent insider buying activity may interest investors. However, it's important to remember that analyst ratings are based on past data and do not guarantee future performance.
Related Filing Alerts
Source: Baird's rating change on $RGNX (Jun 22, 2026). Written by software, not financial advice. How we make alerts